Antibe Therapeutics Inc. ATE.TO
Set alert
As of Apr 8, 3:59 PM ET
52-week range unavailable
- Open
- 0.26
- Prev close
- 0.295
- Mkt cap
- 15.64M
- Vol
- 167.04K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.26
- High
- 0.35
- Forward P/E
- -0.66
- Beta
- 0.19
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.3182
- 200-d avg
- 0.633625
- 1y target
- 0.50
6M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Apr 5, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 1, 2024 | 2 years ago |
| RSI: Oversold | Apr 1, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 25, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 4, 2024 | 2 years ago |
| RSI: Oversold | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Mar 1, 2024 | 2 years ago |
| SMA: Bearish | Feb 29, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 22, 2024 | 2 years ago |
| SMA: Bearish | Feb 13, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 16, 2024 | 2 years ago |
| RSI: Overbought | Jan 4, 2024 | 2 years ago |
| RSI: Overbought | Dec 18, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 14, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 15, 2023 | 2 years ago |
Key statistics
- Market cap
- 15.64M
- Enterprise value
- -9.37M
- Trailing P/E
- 0.00
- Forward P/E
- -0.66
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.60
- EPS (TTM)
- -0.35
- Beta
- 0.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.28M
- Total cash
- 24.91M
- Total debt
- 0
- Return on equity
- -52.73%
- Shares outstanding
- 53.01M
- Short % of float
- 0.00%
- 50-day average
- 0.3182
- 200-day average
- 0.633625
Analyst view
Consensus: hold
Next earnings
Consensus EPS estimate -0.09.
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- antibethera.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ATE.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Curtis (Scott Wilson) | Senior Officer of Issuer | Acquisition or disposition in the public market | Nov 14, 2022 | 100,000 |
| Flower, Roderick John | Director of Issuer | Exercise of rights | Nov 14, 2022 | 151,468 |
| Hoffman (Robert) | Director of Issuer | Exercise of rights | Nov 14, 2022 | 13,334 |
| Khouri, Amal | Director of Issuer | Exercise of rights | Nov 14, 2022 | 1,667 |
| Legault (Daniel Marcel) | Director of Issuer | Acquisition or disposition in the public market | Nov 14, 2022 | 983,296 |
| Mcnealey Jennifer Isacoff | Director of Issuer | Exercise of rights | Nov 14, 2022 | 13,334 |